NCT03036501View on ClinicalTrials.gov

A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Healthy
Interventions
DRUG

[^14C]-Risdiplam

\[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.

Trial Locations (1)

9728 NZ

Pra International Group B.V, Groningen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03036501 - A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants | Biotech Hunter | Biotech Hunter